Announcements Trials

Browse Landscape

Phase

Status

Recruiting 4 Terminated 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1

Interventions

Rituximab 66 Cyclophosphamide 52 fludarabine phosphate 26 fludarabine 22 Filgrastim 21 Vincristine 19 Methotrexate 19 Melphalan 19 Doxorubicin 18 Radiotherapy 17 Etoposide 17 Prednisone 16 Tacrolimus 15 Whole-Body Irradiation 14 Mycophenolic Acid 14 Cytarabine 14 Peripheral Blood Stem Cell Transplantation 13 Gemcitabine 13 Cyclosporine 13 Antilymphocyte Serum 13 Lenalidomide 12 Busulfan 11 Bortezomib 11 Granulocyte Colony-Stimulating Factor 9 Alemtuzumab 9 sargramostim 8 Dexamethasone 8 Cord Blood Stem Cell Transplantation 8 pembrolizumab 7 ibritumomab tiuxetan 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Lymphoma × glofitamab × Clear all

NCT05896163 2026-05-06

MAPtivate-6

Pfizer

Phase 1/2 Terminated

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡